Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study

Boris Decourt, Aaron Walker, Amanda Gonzales, Michael Malek-Ahmadi, Carolyn Liesback, Kathryn J. Davis, Christine M. Belden, Sandra A. Jacobson, Marwan N. Sabbagh

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.

Original languageEnglish (US)
Pages (from-to)235-238
Number of pages4
JournalPlatelets
Volume24
Issue number3
DOIs
StatePublished - Apr 8 2013

    Fingerprint

Keywords

  • Alzheimer's disease
  • BACE1
  • Biomarker
  • Peripheral
  • Platelets

ASJC Scopus subject areas

  • Hematology

Cite this

Decourt, B., Walker, A., Gonzales, A., Malek-Ahmadi, M., Liesback, C., Davis, K. J., Belden, C. M., Jacobson, S. A., & Sabbagh, M. N. (2013). Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study. Platelets, 24(3), 235-238. https://doi.org/10.3109/09537104.2012.688899